Use of antibiotics in patients with Crohn's disease: A systematic review and meta-analysis

Journal of Digestive Diseases

Volumn 16, Issue 2, 2015, Pages 58-66

  Su, Jie Wen ^a   Ma, Jing Jing ^a   Zhang, Hong Jie ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Anti bacterial agents; Ciprofloxacin; Crohn disease; Inflammatory bowel diseases; Meta analysis

Indexed keywords

ANTIBIOTIC AGENT; BUDESONIDE; CIPROFLOXACIN; CLARITHROMYCIN; INFLIXIMAB; METRONIDAZOLE; NITROIMIDAZOLE; ORNIDAZOLE; PLACEBO; PREDNISONE; RIFAXIMIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ANUS FISTULA; ARTICLE; CROHN DISEASE; DRUG EFFICACY; HUMAN; INFLAMMATORY BOWEL DISEASE; INTENTION TO TREAT ANALYSIS; META ANALYSIS; PRIORITY JOURNAL; REMISSION; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; CROHN DISEASE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84923301563     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/1751-2980.12216     Document Type: Article

References (38)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-429.
2. Eckburg PB, Relman DA. The role of microbes in Crohn's disease. Clin Infect Dis 2007; 44: 256-262.
3. Pineton de Chambrun G, Colombel JF, Poulain D, Darfeuille-Michaud A. Pathogenic agents in inflammatory bowel diseases. Curr Opin Gastroenterol 2008; 24: 440-447.
4. Liu Y, van Kruiningen HJ, West AB, Cartun RW, Cortot A, Colombel JF. Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn's disease. Gastroenterology 1995; 108: 1396-1404.
5. Feller M, Huwiler K, Stephan R etal. Mycobacterium avium subspecies paratuberculosis and Crohn's disease: a systematic review and meta-analysis. Lancet Infect Dis 2007; 7: 607-613.
6. Hugot JP, Alberti C, Berrebi D, Bingen E, Cézard JP. Crohn's disease: the cold chain hypothesis. Lancet 2003; 362: 2012-2015.
7. Darfeuille-Michaud A, Boudeau J, Bulois P etal. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2004; 127: 412-421.
8. Ryan P, Kelly RG, Lee G etal. Bacterial DNA within granulomas of patients with Crohn's disease - detection by laser capture microdissection and PCR. Am J Gastroenterol 2004; 99: 1539-1543.
9. Leiper K, Martin K, Ellis A, Watson AJ, Morris AI, Rhodes JM. Clinical trial: randomized study of clarithromycin versus placebo in active Crohn's disease. Aliment Pharmacol Ther 2008; 27: 1233-1239.
10. Goodgame RW, Kimball K, Akram S etal. Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. Aliment Pharmacol Ther 2001; 15: 1861-1866.
11. Guslandi M. Rifaximin in the treatment of inflammatory bowel disease. World J Gastroenterol 2011; 17: 4643-4646.
12. Dewint P, Hansen BE, Verhey E etal. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut 2014; 63: 292-299.
13. Edlund C, Nord CE. Effect of quinolones on intestinal ecology. Drugs 1999; 58 Suppl 2: 65-70.
14. Sundvall PD, Elm M, Gunnarsson R etal. Antimicrobial resistance in urinary pathogens among Swedish nursing home residents remains low: a cross-sectional study comparing antimicrobial resistance from 2003 to 2012. BMC Geriatr 2014; 14: 30.
15. Kaminski MM, Sauer SW, Klemke CD etal. Mitochondrial reactive oxygen species control T cell activation by regulating IL-2 and IL-4 expression: mechanism of ciprofloxacin-mediated immunosuppression. J Immunol 2010; 184: 4827-4841.
16. Herfarth HH, Katz JA, Hanauer SB etal. Ciprofloxacin for the prevention of postoperative recurrence in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2013; 19: 1073-1079.
17. Chao GQ, Zhang S. Effectiveness of acupuncture to treat irritable bowel syndrome: a meta-analysis. World J Gastroenterol 2014; 20: 1871-1877.
18. Prantera C, Zannoni F, Scribano ML etal. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996; 91: 328-332.
19. Thia KT, Mahadevan U, Feagan BG etal. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2009; 15: 17-24.
20. West RL, van der Woude CJ, Hansen BE etal. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2004; 20: 1329-1336.
21. Steinhart AH, Feagan BG, Wong CJ etal. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 2002; 123: 33-40.
22. Arnold GL, Beaves MR, Pryjdun VO, Mook WJ. Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm Bowel Dis 2002; 8: 10-15.
23. Maeda Y, Ng SC, Durdey P etal.; Topical Metronidazole in Perianal Crohn's Study Group. Randomized clinical trial of metronidazole ointment versus placebo in perianal Crohn's disease. Br J Surg 2010; 97: 1340-1347.
24. Mañosa M, Cabré E, Bernal I etal. Addition of metronidazole to azathioprine for the prevention of postoperative recurrence of Crohn's disease: a randomized, double-blind, placebo-controlled trial. Inflamm Bowel Dis 2013; 19: 1889-1895.
25. Rutgeerts P, Van Assche G, Vermeire S etal. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2005; 128: 856-861.
26. Prantera C, Lochs H, Campieri M etal. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther 2006; 23: 1117-1125.
27. Prantera C, Lochs H, Grimaldi M, Danese S, Scribano ML, Gionchetti P; Retic Study Group (Rifaximin-Eir Treatment in Crohn's Disease). Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology 2012; 142: 473-481. e4.
28. Selby W, Pavli P, Crotty B etal.; Antibiotics in Crohn's Disease Study Group. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology 2007; 132: 2313-2319.
29. Sutherland L, Singleton J, Sessions J etal. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991; 32: 1071-1075.
30. Sobczak M, Fabisiak A, Murawska N etal. Current overview of extrinsic and intrinsic factors in etiology and progression of inflammatory bowel diseases. Pharmacol Rep 2014; 66: 766-775.
31. Scott FI, Osterman MT. Medical management of crohn disease. Clin Colon Rectal Surg 2013; 26: 67-74.
32. Wang SL, Wang ZR, Yang CQ. Meta-analysis of broad-spectrum antibiotic therapy in patients with active inflammatory bowel disease. Exp Ther Med 2012; 4: 1051-1056.
33. Khan KJ, Ullman TA, Ford AC etal. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 661-673.
34. Borgaonkar MR, MacIntosh DG, Fardy JM. A meta-analysis of antimycobacterial therapy for Crohn's disease. Am J Gastroenterol 2000; 95: 725-729.
35. Huang J, Liao C, Wu L, Cao Y, Gao F. A meta-analysis of randomized controlled trials comparing antibacterial therapy with placebo in Crohn's disease. Colorectal Dis 2011; 13: 617-626.
36. Ishikawa T, Okamura S, Oshimoto H, Kobayashi R, Mori M. Metronidazole plus ciprofloxacin therapy for active Crohn's disease. Intern Med 2003; 42: 318-321.
37. Dejaco C, Harrer M, Waldhoer T, Miehsler W, Vogelsang H, Reinisch W. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. Aliment Pharmacol Ther 2003; 18: 1113-1120.
38. Park SK, Kim KJ, Lee SO etal. Ciprofloxacin usage and bacterial resistance patterns in Crohn's disease patients with abscesses. J Clin Gastroenterol 2014; 48: 703-707.